1 Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based

2

ART in urban Zimbabwe: A longitudinal study

- 3 Tinei Shamu^{1,2,3*}, Matthias Egger^{2,4,5}, Tinashe Mudzviti^{1,6}, Cleophas Chimbetete¹,
- 4 Justen Manasa⁷, Nanina Anderegg^{1,4}
- 5 ¹ Newlands Clinic, Harare, Zimbabwe
- 6 ² Institute of Social and Preventive Medicine, University of Bern, Switzerland
- ³ Graduate School of Health Sciences, University of Bern, Switzerland
- 8 ⁴ Centre for Infectious Disease Epidemiology and Research, School of Public Health, University
- 9 of Cape Town, Cape Town, South Africa
- ⁵ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United
- 11 Kingdom
- ⁶ Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare,
- 13 Zimbabwe
- ⁷ Innovation Hub, University of Zimbabwe, Harare, Zimbabwe
- 15 * Corresponding Author
- 16 E-mail: tineis@newlandsclinic.org.zw (TS)

17 Abstract

There are few data from sub-Saharan Africa on the virological outcomes associated with 18 second-line ART based on protease inhibitors or dolutegravir (DTG). We compared viral load 19 20 (VL) suppression among people living with HIV (PLWH) on atazanavir (ATV/r)- or dolutegravir (DTG)-based second-line ART with PLWH on efavirenz (EFV)-based first-line ART. We 21 analyzed data from the electronic medical records system of Newlands Clinic in Harare, 22 Zimbabwe. We included patients aged ≥ 12 years when commencing first-line EFV-based ART or 23 switching to second-line DTG- or ATV/r-based ART with ≥24 weeks follow-up after start or 24 switch. We computed suppression rates (HIV VL <50 copies/mL) at weeks 12, 24, 48, 72, and 96 25 and estimated the probability of VL suppression by treatment regimen, time since start/switch of 26 ART, sex, age, and CD4 cell count (at start/switch) using logistic regression in a Bayesian 27 28 framework. We included 7013 VL measurements of 1049 PLWH (61% female) initiating first-line ART and 1114 patients (58% female) switching to second-line ART. Among those switching, 872 29 30 (78.3%) were switched to ATV/r and 242 (21.7%) to DTG. VL suppression was lower in second-31 line ART patients than first-line ART patients, except at week 12, when those on DTG showed higher suppression than those on EFV (aOR 2.10, 95%-credible interval [CrI] 1.48-3.00) and 32 ATV/r-based regimens (aOR 1.87, 95%-CrI 1.32-2.71). In weeks ≥48, first-line patients had 33 around 3 times the odds of VL suppression compared to second-line patients. There was no 34 evidence of a difference between DTG and ATV/r for follow-up times >24 weeks in PLWH on 35 second-line. Second-line ART patients had lower VL suppression rates than those receiving first-36 line ART, and there was no difference in suppression between DTG- and ATV/r-based second-37 line ART >6 months after switching. Virologic monitoring and adherence support remain essential 38 39 to prevent second-line treatment failure in settings with limited treatment options.

40 Introduction

Antiretroviral therapy (ART) has become more effective, more affordable, and safer since 41 the advent of combination therapy in the mid-90s [1]. Currently, the integrase inhibitor 42 dolutegravir (DTG) in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) 43 is recommended for patients initiating ART and for second-line ART among patients who 44 experienced virologic failure on regimens that did not include DTG [2]. Previously, efavirenz 45 (EFV) was recommended for first-line, and the ritonavir-boosted protease inhibitors atazanavir 46 (ATV/r) or lopinavir (LPV/r) for second-line ART, always combined with two NRTIs. DTG 47 achieves earlier virologic suppression compared to ritonavir-boosted protease inhibitors, has fewer 48 toxicities and may have a lower or similar incidence of resistance among patients receiving second-49 line ART [2–4]. Compared with efavirenz, DTG had superior viral suppression over 96 weeks, 50 was protective against drug resistance, and led to fewer discontinuations [5–7]. 51

The success of second-line ART depends on several factors. Poor adherence to treatment has 52 been identified in many studies as the critical determinant of virologic failure and the emergence 53 of drug resistance [8,9]. A high viral load, a low CD4 cell count or advanced HIV infection at the 54 55 time of switching, concomitant treatment for tuberculosis, and younger age are also associated with poorer outcomes on second-line ART [10–13]. The availability of DTG in a fixed dose 56 57 combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), commonly referred 58 to as TLD, may improve treatment compliance and lead to better virologic suppression rates among people living with HIV (PLWH) on second-line ART [2]. 59

60 Compared with boosted protease inhibitors for ART naïve and treatment-experienced
61 PLWH with background NRTI resistance, DTG was neither inferior nor superior for viral

suppression [14-16]. In PLWH switching to DTG-based second-line ART, viral replication is 62 typically reduced to undetectable levels within the first four to 24 weeks of therapy [17,18]. 63 However, long-term real-world virologic suppression and clinical outcomes after switching to 64 second-line ART are less well documented. Indeed, there is a lack of data on the outcomes 65 associated with second-line ART based on boosted protease inhibitors and second-line and first-66 67 line ART based on DTG-containing regimens, particularly in sub-Saharan Africa. We compared virologic suppression among adolescents and adults switching to DTG- or ATV/r-based second-68 line ART after experiencing virologic failure with those starting EFV-based first-line ART in an 69 70 HIV care and treatment program in Zimbabwe.

71 Methods

72 Setting and data

We analyzed data of patients receiving ART at Newlands Clinic in Harare, Zimbabwe. 73 Newlands Clinic is an outpatient HIV referral centre with approximately 7,300 patients in care as 74 of June 2022. The clinic provides comprehensive HIV care to clients of low socio-economic status, 75 including ART, laboratory monitoring, psychosocial support, reproductive health care and other 76 77 ancillary services. It is supported by the Ruedi Luethy Foundation, a Swiss-based private voluntary organization, and part of the International epidemiology Databases to Evaluate AIDS (IeDEA) in 78 Southern Africa. More details on the clinic's activities are provided elsewhere [19,20]. From 2010 79 to 2019, EFV-based ART was predominantly used as first-line ART and ATV/r as second-line 80 ART at Newlands Clinic. Since 2019, DTG-based ART has been used both in first- and second-81 line ART [2,21]. 82

The present analysis was based on the database compiled from the clinic's electronic 83 medical records system. The system is password protected, and only approved clinic staff can log 84 in and view patient records in accordance with the level of permission. We abstracted longitudinal 85 data of patients receiving ART between February 2013 and June 2022, including demographic 86 information, CD4 cell counts, and HIV-1 RNA viral loads. Viral loads were typically measured at 87 the time of switching or starting (baseline). After baseline, viral loads were measured at weeks 12 88 and 24 and then every 24 weeks. Measurements were done using the COBAS 89 Ampliprep/Taqman48 platform and Roche HIV-1 version 1.0 kits. CD4 counts were measured at 90 91 baseline using a Partec Cyflow Counter II machine with CD4 Easy Count reagents by Sysmex.

Patients enrolling into care at Newlands Clinic provided informed written consent that allows the use of data accumulating during their routine care for research under the IeDEA collaboration. IeDEA was approved by the Medical Research Council of Zimbabwe (MRCZ No. A1336) [22]. The study data were stored in a password protected electronic medical records system and were accessed on the 30th of August 2022 by authorised clinic personnel. The abstracted data were supplied to the statistical analysis team as de-identified records that could not be traced to individual patients.

99 Inclusion criteria

We included patients aged 12 years and older at the time of commencing ART or switching to second-line ART who had at least 24 weeks on the new ART regimen. For patients commencing ART, we included those starting with a regimen containing EFV, lamivudine (3TC) and one of tenofovir (TDF), zidovudine (AZT), or abacavir (ABC). For second-line ART, we included patients switching with a viral load above 200 copies/mL from an NNRTI-based first-line to

second-line regimens containing DTG or ATV/r combined with an NRTI backbone, as describedabove.

107 **Outcome**

The outcome of interest was viral load suppression (HIV viral load <50 copies/mL) at week 108 12, 24, 48, 72 and 96 after baseline, in line with the clinic visits with scheduled VL measurements. 109 We allowed for a one-month window around these time points to account for shifts in visit dates. 110 For example, the "Week 24" measurements included VL measurements done 24 ± 4 weeks after 111 baseline. If several measurements were available, the one closest to the visit date was chosen for 112 analysis. Some VL measurements fell between two windows (for example, a measurement drawn 113 35 weeks after baseline was neither assigned to "Week 24" nor to "Week 48"). These 114 measurements were used to impute missing VL information when a patient did not have a VL 115 measurement for a visit date but did have a measurement right before and after the window around 116 the visit date. We assumed that the missing measurement indicated suppressed or unsuppressed 117 VL if both measurements (before and after) showed a suppressed or unsuppressed VL. If the 118 measurements before and after were different (suppressed and unsuppressed), we did not impute 119 the VL suppression information for the visit date. 120

121 Explanatory variables

Explanatory variables included the time of the VL measurement (as defined above as Week 123 12, Week 24, Week 48, Week 72, or Week 96 after baseline), the ART regimen, the patient's sex, 124 age and CD4 cell count at baseline. Age at baseline was grouped into 12-19 years, 20-29, 30-39 125 years and \geq 40 years. CD4 cell count at baseline was grouped into 0-199 cells/mm³, 200-349

126 cells/mm³ and \geq 350 cells/mm³. ART regimens included "EFV" for first-line ART, and "ATV/r" 127 and "DTG" for second-line ART.

128 Statistical analysis

We calculated crude proportions of viral load suppression after baseline by ART regimen. 129 We then estimated the probability of viral load suppression using multivariable logistic regression 130 models in a Bayesian framework. To account for the dependence of viral load measurements 131 132 within patients, we included a random intercept by patient. As fixed effects, we included the covariates ART regimen, time since baseline, sex, age and CD4 cell count. We checked if the 133 inclusion of any two-way interaction between covariates improved the model fit in two steps. First, 134 135 we compared model fits of the simple model without any interactions to alternative models containing one single two-way interaction. All two-way interactions for whom the comparison to 136 the simple model showed a difference in expected log pointwise density that was larger two times 137 its standard error were considered "eligible" for inclusion in the final model [23]. In the second 138 step, we looked at all possible combinations of the eligible two-way interactions. The final model 139 was the one with the best fit (again, according to the expected density). 140

We report adjusted odds ratios (aOR) for VL suppression and crude and predicted proportions of VL suppression with 95% credible intervals (CrIs). For both aORs and predicted probabilities, we report marginalized ("sample-averaged") estimates derived by integrating over the distribution of random effects. Next to reporting predicted proportions stratified by all levels of covariates, we also report them standardized and non-standardized by time and treatment regimen. For standardized predictions, we predicted the probability of VL suppression at weeks 12, 24, 48, 72, and 96 for every study patient, assuming they were on DTG, then assuming they

- 148 were on ATV/r and finally on EFV. We then averaged all the predicted probabilities of viral load
- suppression for each treatment regimen and time point. Non-standardized predictions consisted of
- 150 predicting the probability of VL suppression for the observed data only.

152 **Results**

Overall, we included 2163 PLWH (59.9% female), of whom 1114 were switching to 153 second-line ART, and 1049 were initiating first-line ART (Table 1). Patients switching to second-154 line ART were younger (median age 29 years; IOR 19-42) than those starting first-line ART (36 155 years; IQR 28-44). Among the second-line ART patients, 872 (78.3%) switched to ATV/r-based 156 ART, while 242 (21.7%) switched to DTG-based ART (Table 1). Patients switching to ATV/r-157 based second-line ART had lower CD4 cell counts than those switching to DTG or starting an 158 EFV-based first-line regimen (Table 1). The 2163 patients contributed 7413 VL measurements, of 159 which (7181, 96.9%) were observed and 232 (3.0%) imputed. Around three-quarters of patients 160 had a VL measurement at shorter follow-up times (weeks 12, 24, 48), while this proportion was 161 lower for longer follow-up times (Table 1). For DTG, fewer patients had a VL measurement at 162 163 longer follow-up times than the other two regimens. As indicated by the later calendar years of starting/switching ART for DTG, this was mainly due to the follow-up time of patients switching 164 to DTG being too short to contribute VL measurements for later weeks (Table 1). Only a few 165 166 patients were lost to follow-up or died during the follow-up time relevant to this study (Table 1).

	First line EFV	Secon	Second line	
		ATV/r	DTG	
Total	1049	872	242	2163
Female	645 (61.5%)	506 (58.0%)	145 (59.9%)	1296 (59.9%)
Male	404 (38.5%)	366 (42.0%)	97 (40.1%)	867 (40.1%)
Age [years]				
Median (IQR)	36 (28-44)	29 (19-41.25)	28.5 (19-42)	34 (22-43)
12 - 19	97 (9.2%)	224 (25.7%)	67 (27.7%)	388 (17.9%)
20 - 29	202 (19.3%)	219 (25.1%)	58 (24.0%)	479 (22.1%)
30 - 39	348 (33.2%)	161 (18.5%)	49 (20.2%)	558 (25.8%)
40+	402 (38.3%)	268 (30.7%)	68 (28.1%)	738 (34.1%)
CD4 cell count [cells/mm³]				
Median (IQR)	251 (122-363)	182 (73-331)	253 (78-469)	224 (97-360)
<200	426 (40.6%)	461 (52.9%)	98 (40.5%)	985 (45.5%)
200-349	331 (31.6%)	219 (25.1%)	51 (21.1%)	601 (27.8%)
>=350	292 (27.8%)) 192 (22.0%)	93 (38.4%)	577 (26.7%)
Number of viral load measureme	nts			
Median (IQR)	4 (2-4)	4 (3-5)	3 (2-4)	4 (3-4)
Viral load suppression				
at week 12	800 (76.3%)	683 (78.3%)	202 (83.5%)	1685 (77.9%)
at week 24	884 (84.3%)	722 (82.8%)	175 (72.3%)	1781 (82.3%)
at week 48	812 (77.4%)	663 (76.0%)	155 (64.0%)	1630 (75.4%)
at week 72	424 (40.4%)	506 (58.0%)	108 (44.6%)	1038 (48.0%)
at week 96	627 (59.8%)	565 (64.8%)	87 (36.0%)	1279 (59.1%)
Year of ART start/switch				
Median	2016	2017	2021	2017
(IQR)	(2015-2017)	(2016-2018)	(2020-2021)	(2016-2018)
Status at end of follow-up*				
In care	988 (94.2%)	832 (95.4%)	230 (95.0%)	2050 (94.8%)
LTFU	42 (4.0%)	18 (2.1%)	4 (1.7%)	64 (3.0%)
Dead	19 (1.8%)	22 (2.5%)	8 (3.3%)	49 (2.3%)

168 Table 1. Baseline demographic and clinical characteristics of patients by treatment regimen.

* LTFU and Dead correspond to patients who were lost to follow-up or died within the follow-up time
 relevant to this study. In care corresponds to those who remained in care by week 100 after

170 Televant to this study. In care corresponds to those who remained in care by week 100 after 171 starting (witching ADT on at database closure which even some first, EEV, after insure AT)// witching

starting/switching ART or at database closure, whichever came first. EFV, efavirenz; ATV/r, ritonavir-

- boosted atazanavir; DTG, dolutegravir; IQR, interquartile range; LTFU, lost to follow-up.
- 173

174 Crude rates of virologic suppression were lower on second-line ART than first-line ART

175 (<u>Figure 1</u>). The exception was week 12 when the DTG-based regimen showed higher suppression

176 (crude proportion 69.9%, 95%-CrI 63.6-75.9%) than ATV/r (crude proportion 53.9%, 95%-CrI

177 50.1-57.8%) and EFV-based regimens (crude proportion 57.1%, 95%-CrI 53.6-60.5%). Among

the second-line ART regimens, crude rates of virologic suppression for follow-up times greater
than 24 weeks were slightly higher for DTG (73.5%, 95%-CrI 69.7-77.5%) compared to ATV/r
(68.2%, 95%-CrI 66.2-70.0%).

Figure 1. Crude proportions (with 95% credible intervals) of viral load suppression by
treatment regimen and time post switch (ATV/r, DTG) or start (EFV) of ART. EFV,
efavirenz; ATV/r, ritonavir-boosted atazanavir; DTG, dolutegravir.

184

Only the two-way interactions between time and ART regimen and between time and age met the criteria for potential inclusion in the final model. The model including only the time-ART regimen interaction, and the model including both the time-ART regimen and the time-age interaction led to similar model fits, with a slightly better fit for the simpler model (<u>Supplementary</u> <u>Table S1</u>). The final logistic regression model thus only included the two-way interaction between time and ART regimen. The final model fitted the data well, with a few exceptions when there was large uncertainty due to small numbers (<u>Supplementary Figure S1</u>).

The regression model confirmed the higher odds of VL suppression for DTG at short 192 follow-up (aOR 1.87, 95% CrI 1.32-2.71 comparing DTG to ATV/r at Week 12 and aOR 2.10, 193 95% CrI 1.48-3.00 comparing DTG to EFV, Figure 2). While for DTG, the odds of VL suppression 194 did not increase substantially for longer follow-up periods, they did so for patients on ATV/r and 195 even more for those on EFV (Figure 2, Figure 3). After 24 weeks, the estimated odds of VL 196 suppression were relatively stable for both second-line regimens, and there was no evidence of a 197 difference between DTG and ATV/r. For EFV, the odds of VL suppression also reached a stable 198 plateau but slightly later, at 48 weeks. At that time, the odds of VL suppression was estimated to 199

be around 3 times higher than the second-line regimens (Figure 2, Figure 3). Apart from the differences between first- and second-line regimens, the odds of VL suppression were higher for females and increased with age and CD4 cell count (Figure 2). VL suppression was lowest for adolescents, with estimated suppression rates mostly below 75% in adolescents switching to second-line ART and below 60% for those switching with CD4 cell counts below 200 cells/mm³ (Supplementary Figure S1).

Figure 2. Adjusted odds ratios (aOR) for viral load suppression with 95% (red) credible intervals. Results derived from a Bayesian logistic regression model including a random intercept by patient and the covariates sex, baseline age, baseline CD4 cell count, time since start/switch, and ART regimen. The model also includes a two-way interaction between ART regimen and time since start/switch, so that the aORs comparing ART regimens are shown stratified by time. Estimates are marginalized by integration over the distribution of random effects. EFV, efavirenz; ATV/r, ritonavir-boosted atazanavir; DTG, dolutegravir.

Figure 3. Non-standardized (left panel) and standardized (right panel) predicted

214 proportions and 95% credible intervals of viral load suppression by treatment regimen and

time since switch (DTG, ATV/r) or start (EFV). Results from a Bayesian logistic regression

model including a random intercept by patient and the covariates sex, baseline age, baseline CD4

cell count, time since start/switch, ART regimen, and a two-way interaction between time since

start/switch and ART regimen. Estimates are marginalized by integrating over the distribution of

random effects.

Standardized and non-standardized differences in VL suppression rates between regimens were overall similar, but standardization attenuated differences between the two second-line regimens (Figure 3). At week 48, standardized predicted proportions of VL suppression were

89.1% (95% CrI 86.9-90.9%) for EFV, 74.5% (95%-CrI 68.0-80.7%) for DTG, and 72.9% (95%CrI 69.5-76.1%) for ATV/r (Figure 3). Corresponding non-standardized proportions of VL
suppression at week 48 were 90.3% (95%-CrI 88.4-91.9%) for EFV, 72.9% (95%-CrI 66.1-79.3%)
for DTG, and 69.9% (95%-CrI 66.2-73.2%) for ATV/r (Figure 3).

227

228 **Discussion**

In this longitudinal analysis of routine clinical data collected in an urban ART program in 229 Zimbabwe, we examined virologic suppression among PLWH switching to DTG- or ATV/r-based 230 231 second-line ART after experiencing virologic failure, and PLWH starting ART on EFV-based first-line regimens. Suppression rates were highest for first-line patients receiving EFV-based ART 232 from weeks 24 through 96. Older age and higher CD4 cell count at switch or start were associated 233 234 with higher odds of virologic suppression. In contrast, male sex was associated with reduced odds of virologic suppression across all regimens. Our results confirm the more rapid suppression of 235 viral replication with DTG-based ART than EFV-based ART, even if used in second-line ART 236 [3,4]. 237

Our study's limitations include the absence of objective measures of treatment adherence and baseline drug resistance profiles. Also, not all patients had VL measurements taken at all time points, especially in later weeks and patients switching to DTG. This was mainly due to the shorter follow-up time of patients switching to DTG. Contrary to EFV and ATV/r, which were mainly used before 2019 and thus allowed most patients to have ≥ 2 years of follow-up, DTG was only introduced in 2019. Therefore, recently switched patients can only contribute VL measurements to the earlier weeks. Further, many patients switched to DTG-based second-line during the Covid-

19 national lockdown period. The different periods are a limitation of this study, as we cannot
exclude residual confounding by the Covid-19 pandemic or other factors that might have changed
over time.

Our study took advantage of a long-standing, well-characterized cohort with high retention in care and reliable data collection [20]. This is reflected in the fact that we had little loss to followup over the study period and very few missing CD4 counts, which is rare for observational cohorts in similar settings. Another strength lies in using a Bayesian approach, which allowed us to test for many interactions and calculate standardized probabilities of viral load suppression that allow more informative comparisons between treatment regimens correcting for differences in characteristics between first- and second-line patients.

Many of the PLWH on second-line ART will probably have a history of poor adherence, 255 which led to virologic failure on first-line ART and, in some patients, could have led to the 256 development of drug resistance. However, NNRTI pretreatment resistance likely played a more 257 significant role in the last decade [24–27]. Second-line virologic failure (DTG or ATV/r) may 258 more likely be related to poor treatment compliance based on literature showing almost no 259 pretreatment or transmitted drug resistance among protease inhibitor- and INSTI-naïve PLWH in 260 Zimbabwe and the demonstrated efficacy of both DTG and protease inhibitors with suboptimal 261 NRTI backbones [15,25,28–30]. In addition, a longer duration of ART is associated with a higher 262 likelihood of treatment failure [31,32]. Even though both DTG and ATV/r are potent 263 antiretrovirals, with DTG being superior to EFV for both viral suppression and tolerability 264 [5,7,33], the overall suppression rates among the second-line patients were lower than those 265 266 observed for first-line patients in all age groups, sex, and baseline CD4 cell count strata. This suggests that for patients with a history of treatment failure, switching to DTG or ATV/r alone 267

without other adherence support interventions may not be sufficient to reach the programmatic targets of 95% or higher VL suppression [34,35]. Failure to achieve virologic suppression among patients receiving second-line DTG-based ART can expose these patients to the emergence of drug resistance against DTG and the beginning of transmitted drug resistance to the INSTI class. Several cases of acquired and pretreatment DTG resistance have already been reported [36–38].

273 Almost half of the patients analyzed in this study had advanced HIV disease with baseline 274 CD4 cell counts <200cells/mm³. Although lower CD4 cell counts are the consequence of HIV replication, it is unclear why lower baseline CD4 counts are associated with failure to suppress VL 275 276 across all the regimens in this study. Higher viral loads at ART commencement are associated with prolonged durations before viral suppression leading to increased odds of virologic failure on 277 NNRTI containing ART [39,40]. Further, severe immune suppression might indicate a lower 278 commitment to starting/switching ART or engaging in adherence support initiatives, which in turn 279 is likely associated with reduced treatment adherence [35]. Low CD4 cell counts when switching 280 281 to second-line ART may also result from previous loss to follow-up, treatment interruption, or inconsistent clinic visits. Some studies have also shown a relationship between low baseline CD4 282 cell counts and subsequent virologic failure, while another study from Mozambique showed an 283 284 association between higher baseline CD4 cell counts and virologic failure [24,41,42].

Patients switching to second-line ART were younger than those starting first-line. Likewise, younger patients were also less likely to achieve virologic suppression across all regimens. Younger age has previously been associated with poorer adherence and virologic failure without accompanying drug resistance [24,43]. This observation warrants investment in custom treatment support interventions that foster improved treatment adherence among young PLWH.

290 Conclusion

291	Patients receiving second-line ART were less likely to achieve virologic suppression than
292	those on first-line ART, despite switching to robust or even superior regimens. The probability of
293	virologic suppression increased with increasing age and baseline CD4 cell count. Further efforts
294	are needed to enhance treatment adherence among young PLWH and, more broadly, those
295	switching after virologic failure in settings with limited treatment options.

297 Acknowledgements

298 We acknowledge Ruedi Luethy and the Newlands Clinic staff and clients for making this

299 work possible.

300

301 **References**

- Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy:
 challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015;79: 182–194.
 doi:10.1111/bcp.12403
- Global HIV, Hepatitis and Sexually Transmitted Infections Programmes GRC.
 Consolidated guidelines on HIV prevention, testing, treatment, service delivery and
 monitoring: recommendations for a public health approach. Geneva: World Health
 Organization; 2021. Available: https://www.who.int/publications-detail redirect/9789240031593
- Lunzen J van, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12: 111–118. doi:10.1016/S1473-3099(11)70290-0
- Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet.
 2013;52: 981–994. doi:10.1007/s40262-013-0093-2
- Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A, et
 al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1
 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From
 the SINGLE Randomized Clinical Trial. JAIDS J Acquir Immune Defic Syndr. 2015;70:
 515. doi:10.1097/QAI.00000000000790
- Stellbrink H-J, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir
 in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging
 study. AIDS. 2013;27: 1771. doi:10.1097/QAD.0b013e3283612419
- Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative
 efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral
 therapies for first-line HIV treatment: A systematic literature review and network metaanalysis. EClinicalMedicine. 2020;28. doi:10.1016/j.eclinm.2020.100573

329 330 331	8.	Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26: 929–938. doi:10.1097/QAD.0b013e328351f5b2
332 333 334	9.	Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLOS ONE. 2019;14: e0220159. doi:10.1371/journal.pone.0220159
335 336 337	10.	Chkhartishvili N, Sharvadze L, Dvali N, Karchava M, Rukhadze N, Lomtadze M, et al. Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia. AIDS Res Ther. 2014;11: 18. doi:10.1186/1742-6405-11-18
338 339 340	11.	Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, et al. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. AIDS Res Ther. 2021;18: 1–10. doi:10.1186/s12981-021-00338-y
341 342 343	12.	Seid A, Cherie N, Ahmed K. Determinants of Virologic Failure Among Adults on Second Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia. HIVAIDS - Res Palliat Care. 2020;12: 697–706. doi:10.2147/HIV.S278603
344 345 346 347	13.	Gill N, Bergh RV den, Kyaw KWY, Laxmeshwar C, Das M, Rastogi S, et al. Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India. PLOS ONE. 2019;14: e0225631. doi:10.1371/journal.pone.0225631
348 349 350 351 352	14.	Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017;4: e536–e546. doi:10.1016/S2352-3018(17)30095-4
353 354 355	15.	Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. N Engl J Med. 2021;385: 330–341. doi:10.1056/NEJMoa2101609
356 357 358 359 360	16.	Brown D, Kaplan R, Losso M, Brites C, Wang R, Underwood M, et al. Efficacy of second- line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. Antivir Ther. 2022;27: 13596535221077487. doi:10.1177/13596535221077487
361 362 363	17.	Todd S, Rafferty P, Walker E, Hunter M, Dinsmore W, Donnelly C, et al. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. Int J STD AIDS. 2017;28: 1074–1081. doi:10.1177/0956462416688127
364 365 366	18.	Correa A, Monteiro P, Calixto F, Batista J d'Arc L, Ximenes RA de A, Montarroyos UR. Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV. PLOS ONE. 2020;15: e0238052. doi:10.1371/journal.pone.0238052

Chimbetete C, Shamu T, Keiser O. Zimbabwe's national third-line antiretroviral therapy
 program: Cohort description and treatment outcomes. PLOS ONE. 2020;15: e0228601.
 doi:10.1371/journal.pone.0228601

- Shamu T, Chimbetete C, Shawarira–Bote S, Mudzviti T, Luthy R. Outcomes of an HIV
 cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe:
 TENART cohort. PLOS ONE. 2017;12: e0186726. doi:10.1371/journal.pone.0186726
- Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in
 Zimbabwe, 2016. National Medicines and Therapeutics Policy Advisory Committee
 (NMTPAC) and The AIDS and TB Directorate, Ministry of Health and Child Care,
 Zimbabwe; 2016.
- 22. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al.
 International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa,
 2012-2019. BMJ Open. 2020;10: e035246. doi:10.1136/bmjopen-2019-035246
- Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out
 cross-validation and WAIC. Stat Comput. 2017;27: 1413–1432. doi:10.1007/s11222-016 9696-4
- Lailulo Y, Kitenge M, Jaffer S, Aluko O, Nyasulu PS. Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis. Syst Rev. 2020;9: 292. doi:10.1186/s13643-020-01524-1
- Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, McGregor AM.
 Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line
 Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based
 First-Line Regimens? AIDS Res Hum Retroviruses. 2021;37: 776–783.
 doi:10.1089/AID.2020.0242
- Neuhann F, de Forest A, Heger E, Nhlema A, Scheller C, Kaiser R, et al. Pretreatment
 resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in
 urban Malawi. AIDS Res Ther. 2020;17: 22. doi:10.1186/s12981-020-00282-3
- Boender TS, Hoenderboom BM, Sigaloff KCE, Hamers RL, Wellington M, Shamu T, et al.
 Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin
 Infect Dis Off Publ Infect Dis Soc Am. 2015;61: 1749–1758. doi:10.1093/cid/civ656
- Mungati M, Mhangara M, Gonese E, Mugurungi O, Dzangare J, Ngwende S, et al. Pretreatment drug resistance among patients initiating antiretroviral therapy (ART) in
 Zimbabwe: 2008–2010. BMC Res Notes. 2016;9: 302. doi:10.1186/s13104-016-2101-8
- 401 29. Madyadi A, Dhoro M, Shamu T, Washaya T, Kouamou V, Chimukangara B, et al. HIV-1
 402 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor403 Naive Patients in Harare, Zimbabwe. AIDS Res Hum Retroviruses. 2021;37: 954–961.
 404 doi:10.1089/aid.2021.0084

- 405 30. Maartens G, Meintjes G. Resistance matters in EARNEST. Lancet HIV. 2017;4: e323–
 406 e324. doi:10.1016/S2352-3018(17)30087-5
- Mehari EA, Muche EA, Gonete KA. Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia. HIVAIDS Auckl NZ. 2021;13: 709–717. doi:10.2147/HIV.S316776
- Getawa S, Fentahun A, Adane T, Melku M. Antiretroviral Treatment Failure and Associated Factors Among HIV-Infected Children on Antiretroviral Therapy: A Retrospective Study. HIVAIDS - Res Palliat Care. 2021;13: 229–237. doi:10.2147/HIV.S294046
- 415 33. Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, Balboa-Barreiro V, Martín416 Herranz I, Castro-Iglesias Á, et al. Discontinuation due to neuropsychiatric adverse events
 417 with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
 418 Eur J Hosp Pharm. 2022;29: 207–211. doi:10.1136/ejhpharm-2020-002374
- 419 34. Frescura L, Godfrey-Faussett P, Feizzadeh A. A, El-Sadr W, Syarif O, Ghys PD. Achieving
 420 the 95 95 targets for all: A pathway to ending AIDS. PLoS ONE. 2022;17: e0272405.
 421 doi:10.1371/journal.pone.0272405
- 422 35. Kasimonje B, Shamu T, Mudzviti T, Luethy R. Group counselling for adherence support
 423 among young people failing first-line antiretroviral therapy in Zimbabwe. South Afr J HIV
 424 Med. 2021;22. doi:10.4102/sajhivmed.v22i1.1292
- 36. Chimbetete C, Chirimuta L, Pascoe M, Keiser O. A case report of untreatable HIV infection
 in Harare, Zimbabwe. South Afr J HIV Med. 2019;20: 1–4.
 doi:10.4102/sajhivmed.v20i1.885
- 428 37. Chirimuta LAM, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naïve,
 429 treatment experienced patients from Zimbabwe. South Afr J HIV Med. 2022;23: 3.
 430 doi:10.4102/sajhivmed.v23i1.1435
- 431 38. van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB, et al.
 432 Dolutegravir Resistance in Malawi's National HIV Treatment Program. Open Forum Infect
 433 Dis. 2022;9: ofac148. doi:10.1093/ofid/ofac148
- 39. Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Impact of baseline HIV-1
 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of
 12,370 patients in 21 clinical trials*. HIV Med. 2013;14: 284–292. doi:10.1111/hiv.12004
- 40. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of Drug Resistance in HIV Type 1– Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A
 Systematic Review of Clinical Trials. Clin Infect Dis. 2008;47: 712–722. doi:10.1086/590943

441 442 443 444	41.	Greig JE, Cros PA du, Mills C, Ugwoeruchukwu W, Etsetowaghan A, Grillo A, et al. Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study. PLOS ONE. 2013;8: e71407. doi:10.1371/journal.pone.0071407
445 446 447 448	42.	Palladino C, Briz V, Bellón JM, Bártolo I, Carvalho P, Camacho R, et al. Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. PLOS ONE. 2013;8: e82718. doi:10.1371/journal.pone.0082718
449 450 451	43.	Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, et al. HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe. Open Forum Infect Dis. 2018;5: ofy005. doi:10.1093/ofid/ofy005
452		

453 Supporting information

- 454 S1 Table. Model comparison: Difference in expected log pointwise predictive density
- (ELPD) and its standard error for a new dataset estimated by approximate leave-one out
- 456 cross validation.
- 457 S2 Figure. Predicted (colour) and crude/observed (black) proportions (with 95% credible
- 458 intervals) of viral load suppression stratified by all covariates included in the model fit.




Figure 2




Figure 3




Figure 1